The Bulletin


.

First Patient Dosed in Phase II Renal Cancer Theranostics Study

  • Written by PR Newswire
First Patient Dosed in Phase II Renal Cancer Theranostics Study

MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177Lu-DOTA-girentuximab), at Memorial Sloan Kettering Cancer...

The Bulletin Magazine

Custom Clutches for Unique Vehicle Needs

Why Resolving Your Family Law Matters Quickly is Crucial

Common Signs of Commercial Plumbing Issues and How to Address Them

Maintenance Tips for Your Boat Winch: Keeping It in Top Condition

What Size Shed Needs a Permit in Australia?

Boosting Community Welfare: The Role of Local Government Consulting

Host Events Is Revolutionizing Wedding Planning in Australia

The Best Australian-Made Pet Products

Limitless Creativity: DIY Projects Elevated with Enamel Spray Cans